Pipeline development activities of Abdominal Aortic Aneurysm
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Abdominal Aortic Aneurysm with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Abdominal Aortic Aneurysm treatment.
- Abdominal Aortic Aneurysm key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Abdominal Aortic Aneurysm market.
The dynamics of Abdominal Aortic Aneurysm market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rise in the awareness of the disease, and incremental healthcare spending across the world. The current pipeline of Abdominal Aortic Aneurysm is limited as only a few companies are working on Abdominal Aortic Aneurysm.
It provides an opportunity for other companies to enter the market and grab a significant market share. A few companies are also involved in developing Medical devices for the Abdominal Aortic Aneurysm treatment. Key Players such as Merck Serono and AstraZeneca are involved in developing therapies for Abdominal Aortic Aneurysm.
Launch of emerging therapies, such as Metformin Glucophage (Merck Serono) and Ticagrelor (AstraZeneca) is expected to impact the treatment scenario of Abdominal Aortic Aneurysm significantly. Merck Serono is developing Metformin Glucophage tablets which are being evaluated for the treatment of Abdominal Aortic Aneurysm. At present, it is present in phase II/III stage for the evaluation of safety and Efficacy Study of Metformin as add-on Therapy in Non-diabetic Patients With Abdominal Aortic Aneurysm.
AstraZeneca is developing Ticagrelor for Abdominal Aortic Aneurysm treatment. Currently, it is present in Phase II stage for the evaluation of the efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion. Ticagrelor is a platelet aggregation inhibitor. Additionally, several companies, such as Boston Scientific Corporation (TriVascular Stent-Graft System), Bolton Medical (Treovance stent-graft), Cordis Corporation (Cordis Abdominal Aortic Aneurysmstent graft system), TriVascular (TriVascular Ovation Abdominal Stent Graft System) are also developing medical devices for the treatment of Abdominal Aortic Aneurysm.
Scope of the report
- The Abdominal Aortic Aneurysm report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Abdominal Aortic Aneurysm across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Abdominal Aortic Aneurysm therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Abdominal Aortic Aneurysm research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Abdominal Aortic Aneurysm.
Request for sample pages- https://www.delveinsight.com/sample-request/abdominal-aortic-aneurysm-pipeline-insight
The launch of the emerging therapies is expected to significantly impact Abdominal Aortic Aneurysm treatment scenario in the upcoming years:-
Drugs covered
1. Metformin Glucophage
2. Ticagrelor
And many others
The key players in Abdominal Aortic Aneurysm market are:
1. Merck Serono
2. AstraZeneca
And many others
Request for sample pages- https://www.delveinsight.com/sample-request/abdominal-aortic-aneurysm-pipeline-insight
Table of contents
1. Report Introduction
2. Abdominal Aortic Aneurysm
3. Abdominal Aortic Aneurysm Current Treatment Patterns
4. Abdominal Aortic Aneurysm – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Abdominal Aortic Aneurysm Late Stage Products (Phase-III)
7. Abdominal Aortic Aneurysm Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Abdominal Aortic Aneurysm Discontinued Products
13. Abdominal Aortic Aneurysm Product Profile
14. Abdominal Aortic Aneurysm Key Companies
15. Abdominal Aortic Aneurysm Key Products
16. Dormant and Discontinued Product
17. Abdominal Aortic Aneurysm Unmet Needs
18. Abdominal Aortic Aneurysm Future Perspectives
19. Abdominal Aortic Aneurysm Analyst Review
20. Appendix
21. Report Methodology
The dynamics of Abdominal Aortic Aneurysm market is anticipated tochange in the coming years owing to the improvement in the diagnosismethodologies, rise in the awareness of the disease, and incrementalhealthcare spending across the world. The current pipeline of AbdominalAortic Aneurysm is limited as only a few companies are working on AAA. Itprovides an opportunity for other companies to enter the market and graba significant market share. A few companies are also involved in developingMedical devices for the treatment of AAA.
Key Players such as Merck Serono and AstraZeneca are involved indeveloping therapies for AAA. Launch of emerging therapies, such asMetformin Glucophage (Merck Serono) and Ticagrelor (AstraZeneca) isexpected to impact the treatment scenario of AAA significantly.
Merck Serono is developing Metformin Glucophage tablets which arebeing evaluated for the treatment of Abdominal Aortic Aneurysm. Atpresent, it is present in phase II/III stage for the evaluation of safety andEfficacy Study of Metformin as add-on Therapy in Non-diabetic PatientsWith Abdominal Aortic Aneurysm.
AstraZeneca is developing Ticagrelor for the treatment of AAA. Currently,it is present in Phase II stage for the evaluation of the efficacy of Ticagreloron Abdominal Aortic Aneurysm (AAA) Expansion. Ticagrelor is a plateletaggregation inhibitor.
Additionally, several companies, such as Boston Scientific Corporation(TriVascular Stent-Graft System), Bolton Medical (Treovance stent-graft),Cordis Corporation (Cordis AAA stent graft system), TriVascular(TriVascular Ovation Abdominal Stent Graft System) are also developingmedical devices for the treatment of AAA.
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/